Board of Directors

Dr. Michael Gallatin
ICOS, Calistoga

Dr. Michael Gallatin joined Frazier Healthcare in 2006 as Venture Partner to the Biopharma team. Previously, Dr. Gallatin was Vice President and Scientific Director of ICOS corporation, a former public biopharma company. Dr. Gallatin’s management responsibilities at ICOS included discovery, preclinical research, medchem and process chemistry groups including those that helped generate and support the worldwide registration and launch of Cialis. Subsequently, Dr. Gallatin helped found two Frazier portfolio companies: Cambridge, MA.-based Stromedix, which focuses on novel treatments for chronic fibrotic diseases, and Seattle, WA.-based Calistoga Pharmaceuticals, the first company to demonstrate clinical benefit of isoform selective PI3 kinase inhibition. Calistoga was acquired by Gilead in April 2011 for an up-front payment of $375 million. Dr. Gallatin was President of Calistoga Pharmaceuticals from 2006-2010. He has also been a member of the Scientific Advisory Boards of the Keystone Symposia, Caprion, and the University of Texas Department of Chemistry, and a member of the BioSeek Board of Directors.

Dr. Gallatin received his Ph.D. in 1981 from the University of Alberta Department of Immunology. Dr. Gallatin’s doctoral research focused on genetic resistance to virally induced neoplastic disease and invasive mechanisms including the first description of antigen gain associated with organ-specific tumor metastasis. While a Damon Runyon-Walter Winchell and American Cancer Society fellow at Stanford University in the laboratory of Dr. Irving Weissman, Dr. Gallatin discovered the first cell adhesion molecule implicated in site selective leukocyte traffic. Dr. Gallatin continued his research in the fields of immunology/inflammation and oncology while on the faculty at the Fred Hutchinson Cancer Center prior to his recruitment by Drs. Chris Henney and George Rathmann as one of the founding scientists at ICOS Corporation in 1990.


Dr. Jeffrey Herz, Ph.D.
Founder and CEO, Algomedix

Accomplished innovative pharmacologist, Research Program Director and Project Leader with 19 years experience in directing all phases of non-clinical pharmaceutical research and development. Experienced in moving new drugs though all phases of R&D, from discovery research through entry into clinical trials. Responsible for scientific oversight, execution, analysis and reporting of multiple concurrent in vitro, ex vivo and in vivo studies conducted in-house, outsourced to CROs and academic collaborations. Inventor of 56 issued and allowed pharmaceutical technology patents in multiple therapeutic areas. Goal oriented, attention to detail and proven ability to work in an interdisciplinary team. Trusted by senior management to provide scientific leadership and strategic advice for company critical efforts.


Dr. Leroy Hood
Institute for Systems Biology

Dr. Hood’s outstanding contributions have had a resounding effect on the advancement of science since the 1960s. Throughout his career, he has adhered to the advice of his mentor, Dr. William J. Dreyer: “If you want to practice biology, do it on the leading edge, and if you want to be on the leading edge, invent new tools for deciphering biological information.”

Hood was involved in the development of six instruments critical for contemporary biology—namely, automated DNA sequencers, DNA synthesizers, protein sequencers, peptide synthesizers, the ink jet printer for constructing DNA arrays and large scale synthesis of DNA and the nanostring instrument for the single molecule analysis of RNA (and later DNA). These instruments opened the door to high-throughput biological data and the era of big data in biology and medicine.  He helped pioneer the human genome program—making it possible with the automated DNA sequencer. Under Hood’s direction, the Human Genome Center sequenced portions of human chromosomes 14 and 15.

In 1992, Hood created the first cross-disciplinary biology department, Molecular Biotechnology, at the University of Washington. In 2000, he left the UW to co-found Institute for Systems Biology (ISB), the first committed to systems approach to biology and disease. He has pioneered systems medicine in the years since ISB’s founding and has argued for a healthcare that is predictive, preventive, personalized and participatory (P4). Hood has made many seminal discoveries in the fields of immunology, neurobiology, cancer biology and biotechnology and, most recently, has been a leader in the development of systems biology and its applications to cancer and neurodegenerative diseases, as well as pioneering technologies and strategies that bring systems biology to personalized medicine.

Hood is now pioneering new approaches to P4 medicine and most recently, has embarked on creating a P4 pilot project on 108  well individuals, that is transforming healthcare and leading to a new healthcare discipline termed scientific wellness.

In addition to his groundbreaking research, Hood has published 750 papers, received 36 patents, 17 honorary degrees and more than 100 awards and honors. He is one of only 15 individuals elected to all three National Academies—the National Academy of Science, the National Academy of Engineering, and the National Academy of Medicine. Hood has founded or co-founded 15 different biotechnology companies including Amgen, Applied Biosystems, Rosetta, Darwin, Integrated Diagnostics, Indi Molecular and Arivale.

Hood has also had a life-long interest in K-12 science education and ISB has been a leader in this area.